Abstract
Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.
| Original language | English |
|---|---|
| Pages (from-to) | 1430-1436 |
| Number of pages | 7 |
| Journal | Biochemical and Biophysical Research Communications |
| Volume | 482 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2017 Jan 22 |
Fingerprint
Keywords
- Bazedoxifene
- Eldecalcitol
- Male osteoporosis
- Raloxifene
- Selective estrogen receptor modulators
- Tamoxifen
ASJC Scopus subject areas
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology
Cite this
Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis. / Sato, Yuiko; Tando, Toshimi; Morita, Mayu; Miyamoto, Kana; Kobayashi, Tami; Watanabe, Ryuichi; Oike, Takatsugu; Matsumoto, Morio; Nakamura, Masaya; Miyamoto, Takeshi.
In: Biochemical and Biophysical Research Communications, Vol. 482, No. 4, 22.01.2017, p. 1430-1436.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis
AU - Sato, Yuiko
AU - Tando, Toshimi
AU - Morita, Mayu
AU - Miyamoto, Kana
AU - Kobayashi, Tami
AU - Watanabe, Ryuichi
AU - Oike, Takatsugu
AU - Matsumoto, Morio
AU - Nakamura, Masaya
AU - Miyamoto, Takeshi
PY - 2017/1/22
Y1 - 2017/1/22
N2 - Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.
AB - Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.
KW - Bazedoxifene
KW - Eldecalcitol
KW - Male osteoporosis
KW - Raloxifene
KW - Selective estrogen receptor modulators
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=85028260031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028260031&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2016.12.053
DO - 10.1016/j.bbrc.2016.12.053
M3 - Article
C2 - 27974229
AN - SCOPUS:85028260031
VL - 482
SP - 1430
EP - 1436
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 4
ER -